GF Fund Management CO. LTD. Increases Stock Position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

GF Fund Management CO. LTD. boosted its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 22.0% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 1,548 shares of the specialty pharmaceutical company’s stock after acquiring an additional 279 shares during the quarter. GF Fund Management CO. LTD.’s holdings in Jazz Pharmaceuticals were worth $192,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of JAZZ. IFP Advisors Inc purchased a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at $25,000. Quadrant Capital Group LLC boosted its position in Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 101 shares in the last quarter. Elequin Capital LP grew its stake in Jazz Pharmaceuticals by 677.8% in the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 183 shares during the last quarter. CoreFirst Bank & Trust purchased a new position in Jazz Pharmaceuticals in the fourth quarter valued at about $28,000. Finally, Allianz SE bought a new position in Jazz Pharmaceuticals in the fourth quarter worth about $29,000. Institutional investors own 89.14% of the company’s stock.

Insider Activity at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total transaction of $107,630.00. Following the completion of the transaction, the chief executive officer directly owned 436,973 shares in the company, valued at $47,031,403.99. The trade was a 0.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Seamus Mulligan purchased 1,621 shares of the stock in a transaction on Monday, May 12th. The stock was acquired at an average cost of $103.00 per share, for a total transaction of $166,963.00. Following the completion of the acquisition, the director owned 101,621 shares of the company’s stock, valued at $10,466,963. The trade was a 1.62% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 2,500 shares of company stock valued at $277,930. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Stock Down 0.4%

Jazz Pharmaceuticals stock opened at $109.45 on Friday. The business’s 50-day simple moving average is $108.96 and its two-hundred day simple moving average is $119.07. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.97 and a current ratio of 3.38. The company has a market cap of $6.62 billion, a PE ratio of 14.59, a PEG ratio of 4.72 and a beta of 0.32. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing analysts’ consensus estimates of $4.65 by ($2.97). The firm had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The company’s revenue for the quarter was down .5% compared to the same quarter last year. During the same period last year, the firm earned $2.68 EPS. Equities analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on JAZZ. Royal Bank Of Canada lowered their price target on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an “outperform” rating on the stock in a report on Wednesday, May 7th. Wall Street Zen downgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 15th. Robert W. Baird reduced their price target on Jazz Pharmaceuticals from $167.00 to $155.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 7th. HC Wainwright increased their price objective on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a “buy” rating in a report on Monday, March 10th. Finally, Piper Sandler restated an “overweight” rating and set a $147.00 target price (down from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $184.00.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.